Tercica launches Increlex in the US
Tercica, Inc. (Nasdaq:TRCA) today announced the U.S. commercial launch of Increlex(TM) (mecasermin (rDNA origin) injection), the only recombinant human insulin-like growth factor-1 (rhIGF-1) replacement therapy indicated for the long-term treatment of growth failure in children with severe Primary IGFD. Tercica also announced that following its December 2005 submission for marketing approval in t...Tercica presents two pharmacokinetic studies in an oral session at Endocrine Society Meeting
SAN DIEGO, June 7 /PRNewswire-FirstCall/ -- Tercica, Inc. (Nasdaq: TRCA)...announced today that it presented data from two large pharmacokinetic studies...today in an oral session at the 87th Annual Meeting of the Endocrine Society....The studies demonstrate that following a dose of recombinant human...insulin-like growth factor-1 (rhIGF-1), there is a prompt increase in serum...insulin-like grow...Tercica presents pharmacokinetic and safety data from several studies at Endocrine Society Meeting
San Diego, CA June 6, 2005 Tercica, Inc. (Nasdaq: TRCA) announced...today that it presented data from several studies in poster sessions at the 87th...Annual Meeting of the Endocrine Society. Some of these data are included in...the company's New Drug Application (NDA) for recombinant human Insulin-like...Growth Factor-1 (rhIGF-1) for the treatment of short stature caused by...primary IGF-1 def...